SynthesisFrontiers in immunology2026
Datopotamab deruxtecan in breast cancer treatment: a systematic review of clinical efficacy and safety.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) remains the most common malignant tumor in women worldwide and a leading cause of cancer-related deaths. Despite therapeutic advances, patients with advanced BC, particularly triple-negative breast cancer (TNBC), still face limited effective treatment options. Antibody-drug conjugates (ADCs) represent a compelling strategy that combines precise tumor targeting with cytotoxic payloads, effectively bridging targeted delivery with microenvironmental disruption. Datopotamab deruxtecan (Dato-DXd), a Trop-2-targeted ADC, has demonstrated encouraging clinical activity. Preclinical evidence suggests that Dato-DXd may modulate the tumor microenvironment (TME) through potential induction of immunogenic cell death (ICD), providing a biological rationale for investigating synergistic combinations with immunotherapy. Materials and methods: A systematic review was conducted in accordance with PRISMA guidelines using the PubMed, Web of Science, and ClinicalTrials databases. The inclusion criteria targeted relevant clinical studies published between 2024 and 2026. Ultimately, after a thorough analysis, one randomized controlled trial (RCT) and one single-arm study met the eligibility criteria and were included in the review. Results: Data analysis from the Phase III TROPION-Breast01 trial demonstrated that Dato-DXd significantly improved objective response rate (ORR) and median progression-free survival (PFS) compared to investigator's choice chemotherapy in patients with HR+/HER2- breast cancer. In the Phase I TROPION-PanTumor01 trial, Dato-DXd showed promising clinical activity in both HR+/HER2- breast cancer and TNBC cohorts. Regarding safety, Dato-DXd was associated with a lower incidence of grade ≥ 3 adverse events compared to standard chemotherapy in the randomized setting, although low-grade toxicities such as stomatitis and nausea remained common. Conclusion: Dato-DXd demonstrates robust clinical activity in patients with BC, providing superior disease control with a favorable safety profile compared to conventional chemotherapy. Beyond direct tumor cell ablation, its mechanism of action includes a potent bystander killing effect, while preclinical data suggest that the induction of ICD may contribute to reshaping a heterogeneous TME. Future research is needed to correlate these preclinical mechanistic hypotheses with clinical outcomes. The limited number of available RCTs and Real-World Evidence (RWE) studies underscores the need to raise awareness and conduct further research to identify predictive biomarkers and evaluate combinations with immune checkpoint inhibitors to optimize personalized treatment regimens. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420261408796.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.